Tag Archives: viral

#437171 Scientists Tap the World’s Most ...

Posted on June 4, 2020 by Android

In The Hitchhiker’s Guide to the Galaxy by Douglas Adams, the haughty supercomputer Deep Thought is asked whether it can find the answer to the ultimate question concerning life, the universe, and everything. It replies that, yes, it can do it, but it’s tricky and it’ll have to think about it. When asked how long it will take it replies, “Seven-and-a-half million years. I told you I’d have to think about it.”

Real-life supercomputers are being asked somewhat less expansive questions but tricky ones nonetheless: how to tackle the Covid-19 pandemic. They’re being used in many facets of responding to the disease, including to predict the spread of the virus, to optimize contact tracing, to allocate resources and provide decisions for physicians, to design vaccines and rapid testing tools, and to understand sneezes. And the answers are needed in a rather shorter time frame than Deep Thought was proposing.

The largest number of Covid-19 supercomputing projects involves designing drugs. It’s likely to take several effective drugs to treat the disease. Supercomputers allow researchers to take a rational approach and aim to selectively muzzle proteins that SARS-CoV-2, the virus that causes Covid-19, needs for its life cycle.

The viral genome encodes proteins needed by the virus to infect humans and to replicate. Among these are the infamous spike protein that sniffs out and penetrates its human cellular target, but there are also enzymes and molecular machines that the virus forces its human subjects to produce for it. Finding drugs that can bind to these proteins and stop them from working is a logical way to go.

The Summit supercomputer at Oak Ridge National Laboratory has a peak performance of 200,000 trillion calculations per second—equivalent to about a million laptops. Image credit: Oak Ridge National Laboratory, U.S. Dept. of Energy, CC BY

I am a molecular biophysicist. My lab, at the Center for Molecular Biophysics at the University of Tennessee and Oak Ridge National Laboratory, uses a supercomputer to discover drugs. We build three-dimensional virtual models of biological molecules like the proteins used by cells and viruses, and simulate how various chemical compounds interact with those proteins. We test thousands of compounds to find the ones that “dock” with a target protein. Those compounds that fit, lock-and-key style, with the protein are potential therapies.

The top-ranked candidates are then tested experimentally to see if they indeed do bind to their targets and, in the case of Covid-19, stop the virus from infecting human cells. The compounds are first tested in cells, then animals, and finally humans. Computational drug discovery with high-performance computing has been important in finding antiviral drugs in the past, such as the anti-HIV drugs that revolutionized AIDS treatment in the 1990s.

World’s Most Powerful Computer
Since the 1990s the power of supercomputers has increased by a factor of a million or so. Summit at Oak Ridge National Laboratory is presently the world’s most powerful supercomputer, and has the combined power of roughly a million laptops. A laptop today has roughly the same power as a supercomputer had 20-30 years ago.

However, in order to gin up speed, supercomputer architectures have become more complicated. They used to consist of single, very powerful chips on which programs would simply run faster. Now they consist of thousands of processors performing massively parallel processing in which many calculations, such as testing the potential of drugs to dock with a pathogen or cell’s proteins, are performed at the same time. Persuading those processors to work together harmoniously is a pain in the neck but means we can quickly try out a lot of chemicals virtually.

Further, researchers use supercomputers to figure out by simulation the different shapes formed by the target binding sites and then virtually dock compounds to each shape. In my lab, that procedure has produced experimentally validated hits—chemicals that work—for each of 16 protein targets that physician-scientists and biochemists have discovered over the past few years. These targets were selected because finding compounds that dock with them could result in drugs for treating different diseases, including chronic kidney disease, prostate cancer, osteoporosis, diabetes, thrombosis and bacterial infections.

Scientists are using supercomputers to find ways to disable the various proteins—including the infamous spike protein (green protrusions)—produced by SARS-CoV-2, the virus responsible for Covid-19. Image credit: Thomas Splettstoesser scistyle.com, CC BY-ND

Billions of Possibilities
So which chemicals are being tested for Covid-19? A first approach is trying out drugs that already exist for other indications and that we have a pretty good idea are reasonably safe. That’s called “repurposing,” and if it works, regulatory approval will be quick.

But repurposing isn’t necessarily being done in the most rational way. One idea researchers are considering is that drugs that work against protein targets of some other virus, such as the flu, hepatitis or Ebola, will automatically work against Covid-19, even when the SARS-CoV-2 protein targets don’t have the same shape.

Our own work has now expanded to about 10 targets on SARS-CoV-2, and we’re also looking at human protein targets for disrupting the virus’s attack on human cells. Top-ranked compounds from our calculations are being tested experimentally for activity against the live virus. Several of these have already been found to be active.The best approach is to check if repurposed compounds will actually bind to their intended target. To that end, my lab published a preliminary report of a supercomputer-driven docking study of a repurposing compound database in mid-February. The study ranked 8,000 compounds in order of how well they bind to the viral spike protein. This paper triggered the establishment of a high-performance computing consortium against our viral enemy, announced by President Trump in March. Several of our top-ranked compounds are now in clinical trials.

Also, we and others are venturing out into the wild world of new drug discovery for Covid-19—looking for compounds that have never been tried as drugs before. Databases of billions of these compounds exist, all of which could probably be synthesized in principle but most of which have never been made. Billion-compound docking is a tailor-made task for massively parallel supercomputing.

Dawn of the Exascale Era
Work will be helped by the arrival of the next big machine at Oak Ridge, called Frontier, planned for next year. Frontier should be about 10 times more powerful than Summit. Frontier will herald the “exascale” supercomputing era, meaning machines capable of 1,000,000,000,000,000,000 calculations per second.

Although some fear supercomputers will take over the world, for the time being, at least, they are humanity’s servants, which means that they do what we tell them to. Different scientists have different ideas about how to calculate which drugs work best—some prefer artificial intelligence, for example—so there’s quite a lot of arguing going on.

Hopefully, scientists armed with the most powerful computers in the world will, sooner rather than later, find the drugs needed to tackle Covid-19. If they do, then their answers will be of more immediate benefit, if less philosophically tantalizing, than the answer to the ultimate question provided by Deep Thought, which was, maddeningly, simply 42.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Image credit: NIH/NIAID Continue reading →

Posted in Human Robots

#437103 How to Make Sense of Uncertainty in a ...

Posted on May 1, 2020 by Android

As the internet churns with information about Covid-19, about the virus that causes the disease, and about what we’re supposed to do to fight it, it can be difficult to see the forest for the trees. What can we realistically expect for the rest of 2020? And how do we even know what’s realistic?

Today, humanity’s primary, ideal goal is to eliminate the virus, SARS-CoV-2, and Covid-19. Our second-choice goal is to control virus transmission. Either way, we have three big aims: to save lives, to return to public life, and to keep the economy functioning.

To hit our second-choice goal—and maybe even our primary goal—countries are pursuing five major public health strategies. Note that many of these advances cross-fertilize: for example, advances in virus testing and antibody testing will drive data-based prevention efforts.

Five major public health strategies are underway to bring Covid-19 under control and to contain the spread of SARS-CoV-2.
These strategies arise from things we can control based on the things that we know at any given moment. But what about the things we can’t control and don’t yet know?

The biology of the virus and how it interacts with our bodies is what it is, so we should seek to understand it as thoroughly as possible. How long any immunity gained from prior infection lasts—and indeed whether people develop meaningful immunity at all after infection—are open questions urgently in need of greater clarity. Similarly, right now it’s important to focus on understanding rather than making assumptions about environmental factors like seasonality.

But the biggest question on everyone’s lips is, “When?” When will we see therapeutic progress against Covid-19? And when will life get “back to normal”? There are lots of models out there on the internet; which of those models are right? The simple answer is “none of them.” That’s right—it’s almost certain that every model you’ve seen is wrong in at least one detail, if not all of them. But modeling is meant to be a tool for deeper thinking, a way to run mental (and computational) experiments before—and while—taking action. As George E. P. Box famously wrote in 1976, “All models are wrong, but some are useful.”

Here, we’re seeking useful insights, as opposed to exact predictions, which is why we’re pulling back from quantitative details to get at the mindsets that will support agency and hope. To that end, I’ve been putting together timelines that I believe will yield useful expectations for the next year or two—and asking how optimistic I need to be in order to believe a particular timeline.

For a moderately optimistic scenario to be relevant, breakthroughs in science and technology come at paces expected based on previous efforts and assumptions that turn out to be basically correct; accessibility of those breakthroughs increases at a reasonable pace; regulation achieves its desired effects, without major surprises; and compliance with regulations is reasonably high.

In contrast, if I’m being highly optimistic, breakthroughs in science and technology and their accessibility come more quickly than they ever have before; regulation is evidence-based and successful in the first try or two; and compliance with those regulations is high and uniform. If I’m feeling not-so-optimistic, then I anticipate serious setbacks to breakthroughs and accessibility (with the overturning of many important assumptions), repeated failure of regulations to achieve their desired outcomes, and low compliance with those regulations.

The following scenarios outline the things that need to happen in the fight against Covid-19, when I expect to see them, and how confident I feel in those expectations. They focus on North America and Europe because there are data missing about China’s 2019 outbreak and other regions are still early in their outbreaks. Perhaps the most important thing to keep in mind throughout: We know more today than we did yesterday, but we still have much to learn. New knowledge derived from greater study and debate will almost certainly inspire ongoing course corrections.

As you dive into the scenarios below, practice these three mindset shifts. First, defeating Covid-19 will be a marathon, not a sprint. We shouldn’t expect life to look like 2019 for the next year or two—if ever. As Ed Yong wrote recently in The Atlantic, “There won’t be an obvious moment when everything is under control and regular life can safely resume.” Second, remember that you have important things to do for at least a year. And third, we are all in this together. There is no “us” and “them.” We must all be alert, responsive, generous, and strong throughout 2020 and 2021—and willing to throw away our assumptions when scientific evidence invalidates them.

The Middle Way: Moderate Optimism
Let’s start with the case in which I have the most confidence: moderate optimism.

This timeline considers milestones through late 2021, the earliest that I believe vaccines will become available. The “normal” timeline for developing a vaccine for diseases like seasonal flu is 18 months, which leads to my projection that we could potentially have vaccines as soon as 18 months from the first quarter of 2020. While Melinda Gates agrees with that projection, others (including AI) believe that 3 to 5 years is far more realistic, based on past vaccine development and the need to test safety and efficacy in humans. However, repurposing existing vaccines against other diseases—or piggybacking off clever synthetic platforms—could lead to vaccines being available sooner. I tried to balance these considerations for this moderately optimistic scenario. Either way, deploying vaccines at the end of 2021 is probably much later than you may have been led to believe by the hype engine. Again, if you take away only one message from this article, remember that the fight against Covid-19 is a marathon, not a sprint.

Here, I’ve visualized a moderately optimistic scenario as a baseline. Think of these timelines as living guides, as opposed to exact predictions. There are still many unknowns. More or less optimistic views (see below) and new information could shift these timelines forward or back and change the details of the strategies.
Based on current data, I expect that the first wave of Covid-19 cases (where we are now) will continue to subside in many areas, leading governments to ease restrictions in an effort to get people back to work. We’re already seeing movement in that direction, with a variety of benchmarks and changes at state and country levels around the world. But depending on the details of the changes, easing restrictions will probably cause a second wave of sickness (see Germany and Singapore), which should lead governments to reimpose at least some restrictions.

In tandem, therapeutic efforts will be transitioning from emergency treatments to treatments that have been approved based on safety and efficacy data in clinical trials. In a moderately optimistic scenario, assuming clinical trials currently underway yield at least a few positive results, this shift to mostly approved therapies could happen as early as the third or fourth quarter of this year and continue from there. One approval that should come rather quickly is for plasma therapies, in which the blood from people who have recovered from Covid-19 is used as a source of antibodies for people who are currently sick.

Companies around the world are working on both viral and antibody testing, focusing on speed, accuracy, reliability, and wide accessibility. While these tests are currently being run in hospitals and research laboratories, at-home testing is a critical component of the mass testing we’ll need to keep viral spread in check. These are needed to minimize the impact of asymptomatic cases, test the assumption that infection yields resistance to subsequent infection (and whether it lasts), and construct potential immunity passports if this assumption holds. Testing is also needed for contact tracing efforts to prevent further spread and get people back to public life. Finally, it’s crucial to our fundamental understanding of the biology of SARS-CoV-2 and Covid-19.

We need tests that are very reliable, both in the clinic and at home. So, don’t go buying any at-home test kits just yet, even if you find them online. Wait for reliable test kits and deeper understanding of how a test result translates to everyday realities. If we’re moderately optimistic, in-clinic testing will rapidly expand this quarter and/or next, with the possibility of broadly available, high-quality at-home sampling (and perhaps even analysis) thereafter.

Note that testing is not likely to be a “one-and-done” endeavor, as a person’s infection and immunity status change over time. Expect to be testing yourself—and your family—often as we move later into 2020.

Testing data are also going to inform distancing requirements at the country and local levels. In this scenario, restrictions—at some level of stringency—could persist at least through the end of 2020, as most countries are way behind the curve on testing (Iceland is an informative exception). Governments will likely continue to ask citizens to work from home if at all possible; to wear masks or face coverings in public; to employ heightened hygiene and social distancing in workplaces; and to restrict travel and social gatherings. So while it’s likely we’ll be eating in local restaurants again in 2020 in this scenario, at least for a little while, it’s not likely we’ll be heading to big concerts any time soon.

The Extremes: High and Low Optimism
How would high and low levels of optimism change our moderately optimistic timeline? The milestones are the same, but the time required to achieve them is shorter or longer, respectively. Quantifying these shifts is less important than acknowledging and incorporating a range of possibilities into our view. It pays to pay attention to our bias. Here are a few examples of reasonable possibilities that could shift the moderately optimistic timeline.

When vaccines become available
Vaccine repurposing could shorten the time for vaccines to become available; today, many vaccine candidates are in various stages of testing. On the other hand, difficulties in manufacture and distribution, or faster-than-expected mutation of SARS-CoV-2, could slow vaccine development. Given what we know now, I am not strongly concerned about either of these possibilities—drug companies are rapidly expanding their capabilities, and viral mutation isn’t an urgent concern at this time based on sequencing data—but they could happen.

At first, governments will likely supply vaccines to essential workers such as healthcare workers, but it is essential that vaccines become widely available around the world as quickly and as safely as possible. Overall, I suggest a dose of skepticism when reading highly optimistic claims about a vaccine (or multiple vaccines) being available in 2020. Remember, a vaccine is a knockout punch, not a first line of defense for an outbreak.

When testing hits its stride
While I am confident that testing is a critical component of our response to Covid-19, reliability is incredibly important to testing for SARS-CoV-2 and for immunity to the disease, particularly at home. For an individual, a false negative (being told you don’t have antibodies when you really do) could be just as bad as a false positive (being told you do have antibodies when you really don’t). Those errors are compounded when governments are trying to make evidence-based policies for social and physical distancing.

If you’re highly optimistic, high-quality testing will ramp up quickly as companies and scientists innovate rapidly by cleverly combining multiple test modalities, digital signals, and cutting-edge tech like CRISPR. Pop-up testing labs could also take some pressure off hospitals and clinics.

If things don’t go well, reliability issues could hinder testing, manufacturing bottlenecks could limit availability, and both could hamstring efforts to control spread and ease restrictions. And if it turns out that immunity to Covid-19 isn’t working the way we assumed, then we must revisit our assumptions about our path(s) back to public life, as well as our vaccine-development strategies.

How quickly safe and effective treatments appear
Drug development is known to be long, costly, and fraught with failure. It’s not uncommon to see hope in a drug spike early only to be dashed later on down the road. With that in mind, the number of treatments currently under investigation is astonishing, as is the speed through which they’re proceeding through testing. Breakthroughs in a therapeutic area—for example in treating the seriously ill or in reducing viral spread after an infection takes hold—could motivate changes in the focus of distancing regulations.

While speed will save lives, we cannot overlook the importance of knowing a treatment’s efficacy (does it work against Covid-19?) and safety (does it make you sick in a different, or worse, way?). Repurposing drugs that have already been tested for other diseases is speeding innovation here, as is artificial intelligence.

Remarkable collaborations among governments and companies, large and small, are driving innovation in therapeutics and devices such as ventilators for treating the sick.

Whether government policies are effective and responsive
Those of us who have experienced lockdown are eager for it to be over. Businesses, economists, and governments are also eager to relieve the terrible pressure that is being exerted on the global economy. However, lifting restrictions will almost certainly lead to a resurgence in sickness.

Here, the future is hard to model because there are many, many factors at play, and at play differently in different places—including the extent to which individuals actually comply with regulations.

Reliable testing—both in the clinic and at home—is crucial to designing and implementing restrictions, monitoring their effectiveness, and updating them; delays in reliable testing could seriously hamper this design cycle. Lack of trust in governments and/or companies could also suppress uptake. That said, systems are already in place for contact tracing in East Asia. Other governments could learn important lessons, but must also earn—and keep—their citizens’ trust.

Expect to see restrictions descend and then lift in response to changes in the number of Covid-19 cases and in the effectiveness of our prevention strategies. Also expect country-specific and perhaps even area-specific responses that differ from each other. The benefit of this approach? Governments around the world are running perhaps hundreds of real-time experiments and design cycles in balancing health and the economy, and we can learn from the results.

A Way Out
As Jeremy Farrar, head of the Wellcome Trust, told Science magazine, “Science is the exit strategy.” Some of our greatest technological assistance is coming from artificial intelligence, digital tools for collaboration, and advances in biotechnology.

Our exit strategy also needs to include empathy and future visioning—because in the midst of this crisis, we are breaking ground for a new, post-Covid future.

What do we want that future to look like? How will the hard choices we make now about data ethics impact the future of surveillance? Will we continue to embrace inclusiveness and mass collaboration? Perhaps most importantly, will we lay the foundation for successfully confronting future challenges? Whether we’re thinking about the next pandemic (and there will be others) or the cascade of catastrophes that climate change is bringing ever closer—it’s important to remember that we all have the power to become agents of that change.

Special thanks to Ola Kowalewski and Jason Dorrier for significant conversations.

Image Credit: Drew Beamer / Unsplash Continue reading →

Posted in Human Robots

#436167 Is it Time for Tech to Stop Moving Fast ...

Posted on November 2, 2019 by Android

On Monday, I attended the 2019 Fall Conference of Stanford’s Institute for Human Centered Artificial Intelligence (HAI). That same night I watched the Season 6 opener for the HBO TV show Silicon Valley. And the debates featured in both surrounded the responsibility of tech companies for the societal effects of the technologies they produce. The two events have jumbled together in my mind, perhaps because I was in a bit of a brain fog, thanks to the nasty combination of a head cold and the smoke that descended on Silicon Valley from the northern California wildfires. But perhaps that mixture turned out to be a good thing.

What is clear, in spite of the smoke, is that this issue is something a lot of people are talking about, inside and outside of Silicon Valley (witness the viral video of Rep. Alexandria Ocasio-Cortez (D-NY) grilling Facebook CEO Mark Zuckerberg).

So, to add to that conversation, here’s my HBO Silicon Valley/Stanford HAI conference mashup.

Silicon Valley’s fictional CEO Richard Hendriks, in the opening scene of the episode, tells Congress that Facebook, Google, and Amazon only care about exploiting personal data for profit. He states:

“These companies are kings, and they rule over kingdoms far larger than any nation in history.”

Meanwhile Marietje Schaake, former member of the European Parliament and a fellow at HAI, told the conference audience of 900:

“There is a lot of power in the hands of few actors—Facebook decides who is a news source, Microsoft will run the defense department’s cloud…. I believe we need a deeper debate about which tasks need to stay in the hands of the public.”

Eric Schmidt, former CEO and executive chairman of Google, agreed. He says:

“It is important that we debate now the ethics of what we are doing, and the impact of the technology that we are building.”

Stanford Associate Professor Ge Wang, also speaking at the HAI conference, pointed out:

“‘Doing no harm’ is a vital goal, and it is not easy. But it is different from a proactive goal, to ‘do good.’”

Had Silicon Valley’s Hendricks been there, he would have agreed. He said in the episode:

“Just because it’s successful, doesn’t mean it’s good. Hiroshima was a successful implementation.”

The speakers at the HAI conference discussed the implications of moving fast and breaking things, of putting untested and unregulated technology into the world now that we know that things like public trust and even democracy can be broken.

Google’s Schmidt told the HAI audience:

“I don’t think that everything that is possible should be put into the wild in society, we should answer the question, collectively, how much risk are we willing to take.

And Silicon Valley denizens real and fictional no longer think it’s OK to just say sorry afterwards. Says Schmidt:

“When you ask Facebook about various scandals, how can they still say ‘We are very sorry; we have a lot of learning to do.’ This kind of naiveté stands out of proportion to the power tech companies have. With great power should come great responsibility, or at least modesty.”

Schaake argued:

“We need more guarantees, institutions, and policies than stated good intentions. It’s about more than promises.”

Fictional CEO Hendricks thinks saying sorry is a cop-out as well. In the episode, a developer admits that his app collected user data in spite of Hendricks assuring Congress that his company doesn’t do that:

“You didn’t know at the time,” the developer says. “Don’t beat yourself up about it. But in the future, stop saying it. Or don’t; I don’t care. Maybe it will be like Google saying ‘Don’t be evil,’ or Facebook saying ‘I’m sorry, we’ll do better.’”

Hendricks doesn’t buy it:

“This stops now. I’m the boss, and this is over.”

(Well, he is fictional.)

How can government, the tech world, and the general public address this in a more comprehensive way? Out in the real world, the “what to do” discussion at Stanford HAI surrounded regulation—how much, what kind, and when.

Says the European Parliament’s Schaake:

“An often-heard argument is that government should refrain from regulating tech because [regulation] will stifle innovation. [That argument] implies that innovation is more important than democracy or the rule of law. Our problems don’t stem from over regulation, but under regulation of technologies.”

But when should that regulation happen. Stanford provost emeritus John Etchemendy, speaking from the audience at the HAI conference, said:

“I’ve been an advocate of not trying to regulate before you understand it. Like San Francisco banning of use of facial recognition is not a good example of regulation; there are uses of facial recognition that we should allow. We want regulations that are just right, that prevent the bad things and allow the good things. So we are going to get it wrong either way, if we regulate to soon or hold off, we will get some things wrong.”

Schaake would opt for regulating sooner rather than later. She says that she often hears the argument that it is too early to regulate artificial intelligence—as well as the argument that it is too late to regulate ad-based political advertising, or online privacy. Neither, to her, makes sense. She told the HAI attendees:

“We need more than guarantees than stated good intentions.”

U.S. Chief Technology Officer Michael Kratsios would go with later rather than sooner. (And, yes, the country has a CTO. President Barack Obama created the position in 2009; Kratsios is the fourth to hold the office and the first under President Donald Trump. He was confirmed in August.) Also speaking at the HAI conference, Kratsios argued:

“I don’t think we should be running to regulate anything. We are a leader [in technology] not because we had great regulations, but we have taken a free market approach. We have done great in driving innovation in technologies that are born free, like the Internet. Technologies born in captivity, like autonomous vehicles, lag behind.”

In the fictional world of HBO’s Silicon Valley, startup founder Hendricks has a solution—a technical one of course: the decentralized Internet. He tells Congress:

“The way we win is by creating a new, decentralized Internet, one where the behavior of companies like this will be impossible, forever. Where it is the users, not the kings, who have sovereign control over their data. I will help you build an Internet that is of the people, by the people, and for the people.”

(This is not a fictional concept, though it is a long way from wide use. Also called the decentralized Web, the concept takes the content on today’s Web and fragments it, and then replicates and scatters those fragments to hosts around the world, increasing privacy and reducing the ability of governments to restrict access.)

If neither regulation nor technology comes to make the world safe from the unforeseen effects of new technologies, there is one more hope, according to Schaake: the millennials and subsequent generations.

Tech companies can no longer pursue growth at all costs, not if they want to keep attracting the talent they need, says Schaake. She noted that, “the young generation looks at the environment, at homeless on the streets,” and they expect their companies to tackle those and other issues and make the world a better place. Continue reading →

Posted in Human Robots

#435748 Video Friday: This Robot Is Like a ...

Posted on September 19, 2019 by Android

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):

RSS 2019 – June 22-26, 2019 – Freiburg, Germany
Hamlyn Symposium on Medical Robotics – June 23-26, 2019 – London, U.K.
ETH Robotics Summer School – June 27-1, 2019 – Zurich, Switzerland
MARSS 2019 – July 1-5, 2019 – Helsinki, Finland
ICRES 2019 – July 29-30, 2019 – London, U.K.
DARPA SubT Tunnel Circuit – August 15-22, 2019 – Pittsburgh, Pa., USA
Let us know if you have suggestions for next week, and enjoy today’s videos.

It’s been a while since we last spoke to Joe Jones, the inventor of Roomba, about his solar-powered, weed-killing robot, called Tertill, which he was launching as a Kickstarter project. Tertill is now available for purchase (US $300) and is shipping right now.

[ Tertill ]

Usually, we don’t post videos that involve drone use that looks to be either illegal or unsafe. These flights over the protests in Hong Kong are almost certainly both. However, it’s also a unique perspective on the scale of these protests.

[ Team BlackSheep ]

ICYMI: iRobot announced this week that it has acquired Root Robotics.

[ iRobot ]

This Boston Dynamics parody video went viral this week.

The CGI is good but the gratuitous violence—even if it’s against a fake robot—is a bit too much?

This is still our favorite Boston Dynamics parody video:

[ Corridor ]

Biomedical Engineering Department Head Bin He and his team have developed the first-ever successful non-invasive mind-controlled robotic arm to continuously track a computer cursor.

[ CMU ]

Organic chemists, prepare to meet your replacement:

Automated chemical synthesis carries great promises of safety, efficiency and reproducibility for both research and industry laboratories. Current approaches are based on specifically-designed automation systems, which present two major drawbacks: (i) existing apparatus must be modified to be integrated into the automation systems; (ii) such systems are not flexible and would require substantial re-design to handle new reactions or procedures. In this paper, we propose a system based on a robot arm which, by mimicking the motions of human chemists, is able to perform complex chemical reactions without any modifications to the existing setup used by humans. The system is capable of precise liquid handling, mixing, filtering, and is flexible: new skills and procedures could be added with minimum effort. We show that the robot is able to perform a Michael reaction, reaching a yield of 34%, which is comparable to that obtained by a junior chemist (undergraduate student in Chemistry).

[ arXiv ] via [ NTU ]

So yeah, ICRA 2019 was huge and awesome. Here are some brief highlights.

[ Montreal Gazette ]

For about US $5, this drone will deliver raw meat and beer to you if you live on an uninhabited island in Tokyo Bay.

[ Nikkei ]

The Smart Microsystems Lab at Michigan State University has a new version of their Autonomous Surface Craft. It’s autonomous, open source, and awfully hard to sink.

[ SML ]

As drone shows go, this one is pretty good.

[ CCTV ]

Here’s a remote controlled robot shooting stuff with a very large gun.

[ HDT ]

Over a period of three quarters (September 2018 thru May 2019), we’ve had the opportunity to work with five graduating University of Denver students as they brought their idea for a Misty II arm extension to life.

[ Misty Robotics ]

If you wonder how it looks to inspect burners and superheaters of a boiler with an Elios 2, here you are! This inspection was performed by Svenska Elektrod in a peat-fired boiler for Vattenfall in Sweden. Enjoy!

[ Flyability ]

The newest Soft Robotics technology, mGrip mini fingers, made for tight spaces, small packaging, and delicate items, giving limitless opportunities for your applications.

[ Soft Robotics ]

What if legged robots were able to generate dynamic motions in real-time while interacting with a complex environment? Such technology would represent a significant step forward the deployment of legged systems in real world scenarios. This means being able to replace humans in the execution of dangerous tasks and to collaborate with them in industrial applications.

This workshop aims to bring together researchers from all the relevant communities in legged locomotion such as: numerical optimization, machine learning (ML), model predictive control (MPC) and computational geometry in order to chart the most promising methods to address the above-mentioned scientific challenges.

[ Num Opt Wkshp ]

Army researchers teamed with the U.S. Marine Corps to fly and test 3-D printed quadcopter prototypes a the Marine Corps Air Ground Combat Center in 29 Palms, California recently.

[ CCDC ARL ]

Lex Fridman’s Artificial Intelligence podcast featuring Rosalind Picard.

[ AI Podcast ]

In this week’s episode of Robots in Depth, per speaks with Christian Guttmann, executive director of the Nordic AI Artificial Intelligence Institute.

Christian Guttmann talks about AI and wanting to understand intelligence enough to recreate it. Christian has be focusing on AI in healthcare and has recently started to communicate the opportunities and challenges in artificial intelligence to the general public. This is something that the host Per Sjöborg is also very passionate about. We also get to hear about the Nordic AI institute and the work it does to inform all parts of society about AI.

[ Robots in Depth ] Continue reading →

Posted in Human Robots

#435589 Construction Robots Learn to Excavate by ...

Posted on September 11, 2019 by Android

Pavel Savkin remembers the first time he watched a robot imitate his movements. Minutes earlier, the engineer had finished “showing” the robotic excavator its new goal by directing its movements manually. Now, running on software Savkin helped design, the robot was reproducing his movements, gesture for gesture. “It was like there was something alive in there—but I knew it was me,” he said.

Savkin is the CTO of SE4, a robotics software project that styles itself the “driver” of a fleet of robots that will eventually build human colonies in space. For now, SE4 is focused on creating software that can help developers communicate with robots, rather than on building hardware of its own.
The Tokyo-based startup showed off an industrial arm from Universal Robots that was running SE4’s proprietary software at SIGGRAPH in July. SE4’s demonstration at the Los Angeles innovation conference drew the company’s largest audience yet. The robot, nicknamed Squeezie, stacked real blocks as directed by SE4 research engineer Nathan Quinn, who wore a VR headset and used handheld controls to “show” Squeezie what to do.

As Quinn manipulated blocks in a virtual 3D space, the software learned a set of ordered instructions to be carried out in the real world. That order is essential for remote operations, says Quinn. To build remotely, developers need a way to communicate instructions to robotic builders on location. In the age of digital construction and industrial robotics, giving a computer a blueprint for what to build is a well-explored art. But operating on a distant object—especially under conditions that humans haven’t experienced themselves—presents challenges that only real-time communication with operators can solve.

The problem is that, in an unpredictable setting, even simple tasks require not only instruction from an operator, but constant feedback from the changing environment. Five years ago, the Swedish fiber network provider umea.net (part of the private Umeå Energy utility) took advantage of the virtual reality boom to promote its high-speed connections with the help of a viral video titled “Living with Lag: An Oculus Rift Experiment.” The video is still circulated in VR and gaming circles.

In the experiment, volunteers donned headgear that replaced their real-time biological senses of sight and sound with camera and audio feeds of their surroundings—both set at a 3-second delay. Thus equipped, volunteers attempt to complete everyday tasks like playing ping-pong, dancing, cooking, and walking on a beach, with decidedly slapstick results.

At outer-orbit intervals, including SE4’s dream of construction projects on Mars, the limiting factor in communication speed is not an artificial delay, but the laws of physics. The shifting relative positions of Earth and Mars mean that communications between the planets—even at the speed of light—can take anywhere from 3 to 22 minutes.

A long-distance relationship

Imagine trying to manage a construction project from across an ocean without the benefit of intelligent workers: sending a ship to an unknown world with a construction crew and blueprints for a log cabin, and four months later receiving a letter back asking how to cut down a tree. The parallel problem in long-distance construction with robots, according to SE4 CEO Lochlainn Wilson, is that automation relies on predictability. “Every robot in an industrial setting today is expecting a controlled environment.”
Platforms for applying AR and VR systems to teach tasks to artificial intelligences, as SE4 does, are already proliferating in manufacturing, healthcare, and defense. But all of the related communications systems are bound by physics and, specifically, the speed of light.
The same fundamental limitation applies in space. “Our communications are light-based, whether they’re radio or optical,” says Laura Seward Forczyk, a planetary scientist and consultant for space startups. “If you’re going to Mars and you want to communicate with your robot or spacecraft there, you need to have it act semi- or mostly-independently so that it can operate without commands from Earth.”

Semantic control
That’s exactly what SE4 aims to do. By teaching robots to group micro-movements into logical units—like all the steps to building a tower of blocks—the Tokyo-based startup lets robots make simple relational judgments that would allow them to receive a full set of instruction modules at once and carry them out in order. This sidesteps the latency issue in real-time bilateral communications that could hamstring a project or at least make progress excruciatingly slow.
The key to the platform, says Wilson, is the team’s proprietary operating software, “Semantic Control.” Just as in linguistics and philosophy, “semantics” refers to meaning itself, and meaning is the key to a robot’s ability to make even the smallest decisions on its own. “A robot can scan its environment and give [raw data] to us, but it can’t necessarily identify the objects around it and what they mean,” says Wilson.

That’s where human intelligence comes in. As part of the demonstration phase, the human operator of an SE4-controlled machine “annotates” each object in the robot’s vicinity with meaning. By labeling objects in the VR space with useful information—like which objects are building material and which are rocks—the operator helps the robot make sense of its real 3D environment before the building begins.

Giving robots the tools to deal with a changing environment is an important step toward allowing the AI to be truly independent, but it’s only an initial step. “We’re not letting it do absolutely everything,” said Quinn. “Our robot is good at moving an object from point A to point B, but it doesn’t know the overall plan.” Wilson adds that delegating environmental awareness and raw mechanical power to separate agents is the optimal relationship for a mixed human-robot construction team; it “lets humans do what they’re good at, while robots do what they do best.”

This story was updated on 4 September 2019. Continue reading →

Posted in Human Robots